Sumitomo Dainippon Pharma Annual Report 2017
38/102

¥197.9billion¥83.3billion870Net sales / Income of segment(Billions of yen)240.0180.0120.060.00200.0150.0100.050.00(FY)Net salesIncome of segment* MR: Medical Representative(forecast)2014201520162017Key Measures148.2184.9197.934.765.283.3Brand NameTherapeutic IndicationFY2015FY2016Rate ofchange(%)FY2017forecastLATUDA®BROVANA®APTIOM®Ciclesonide*XOPENEX®Atypical antipsychoticLong-acting beta-agonistAntiepilepticInhaled corticosteroid, Corticosteroid nasal sprayShort-acting beta-agonist120.429.97.67.06.7135.933.111.65.15.112.910.651.3(27.0)(23.5)169.234.416.71.73.2LATUDA® surpassed initial sales forecasts with sales of US$1.25 billion, despite intense market competition, thanks to high quality promotions by MRs dedicated exclusively to LATUDA® since the product’s launch, as well as DTC advertising on television and the Internet.APTIOM® is the only once-daily dose, antiepileptic drug available for monotherapy and adjunctive therapy in the treatment of partial-onset seizures. We significantly expanded sales 51.3% year on year as a result of assigning MRs dedicated exclusively to APTIOM®, concentrating efforts on promoting it as a strategic product, and aggressively working on sales activities.BROVANA® is an inhalant bronchodilator used as a maintenance therapy for COPD. Its use has not only increased in hospitals and pharmacies, but also grown in the home medical care and long-term care (LTC) settings, and it has experienced nine years of continuous revenue growth since its launch in 2007.FY2016 Main Initiatives and Business ResultsIn FY2017, we will focus efforts on expanding sales of existing strategic products LATUDA®, APTIOM®, and BROVANA®, while growing our COPD franchise that is adding new products.We will aim for further growth in sales of LATUDA® by continuing to work on promotion aimed at medical professionals and DTC advertising on the treatment of bipolar I depression. We will continue to increase product recognition for APTIOM® and promote monotherapy.FY2017 Business Plan and OutlookNorth American Market(Billions of yen)Number of MRs (FY2016)Sales of Major Products (Billions of yen)• Further growth for atypical antipsychotic agent LATUDA® and antiepileptic APTIOM®.• Expand sales in the Chronic Obstructive Pulmonary Disease (COPD) area by launching new products245.6100.4* Sunovion entered into a definitive agreement to divest the U.S. market rights to ciclesonide products in July 2017.MarketingPharmaceutical Business37Sumitomo Dainippon Pharma Co., Ltd. Annual Report 2017

元のページ  ../index.html#38

このブックを見る